Introduction: Orthorexia nervosa (ON) is a common phenomenon. Its prevalence in society ranges from 1% to 60%. Yet, there are no specific diagnostic criteria or effective screening tests. Moreover, orthorexia does not appear in any of the available international psychiatric classifications such as the ICD (International Statistical Classification of Diseases and Related Health Problems) and DSM (Diagnostic and Statistical Manual of Mental Disorders). Due to this fact many people remain undiagnosed, which significantly affects their standard of living, and later puts a strain on the health care system. Material and method: The article is based on a study and analysis of available publications in the last few years, published in the PubMed database. Conclusions: It is crucial to create specific diagnostic criteria for orthorexia. This will enable efficient detection of patients at an early stage of the disorder, which will significantly shorten the diagnostic path. Moreover, specifying potential risk factors will help to reduce new cases.

Giardia intestinalis infection is the most common parasitic infection in the world. The parasite's reservoir is mainly humans and many species of mammals. Giardiasis is a parasitic disease of the duodenum and small intestine. Infection spreads easily through the oral-fecal route. Its most frequent symptom is chronic diarrhea, but it can also be asymptomatic. This article analyzes atypical symptoms of Giardia Intestinalis infection based on available studies in the PubMed database. Observations have shown that giardiasis can manifest in various types of dermatoses such as urticaria, angioedema, atopic dermatitis, erythema nodosum, or Wells syndrome. A relationship between Giardia Intestinalis infection and various allergic syndromes, manifesting as chronic urticaria or angioedema, has also been observed, as well as an increased occurrence of food allergies due to increased exposure to antigens. Studies have also shown that giardiasis can cause polyneuropathy, avitaminosis, and malabsorption syndrome. Even years after infection, chronic fatigue syndrome can still be observed

Introduction: Worldwide, cannabis is the most widely used illegal psychoactive substance and the third most common drug, after alcohol and tobacco. Cannabis use disorder (CUD) affects approximately 10% of the 193 million cannabis users worldwide. In recent years, cannabinoids have become more and more popular. The CUD is becoming a growing social and health problem. The search for effective forms of pharmacotherapy is still ongoing, and an effective combination of psychotherapy and pharmacotherapy may be crucial for the future of CUD treatment.   Material and method: The article was based on a review and analysis of publications and discoveries in recent years, which were available in the PubMed and Google Scholar database.   Results: 82 study participants attempted abstinence from cannabis use. In the final primary endpoint analysis, both 400 mg of CBD and 800 mg of CBD were more effective than placebo in reducing cannabis use.  50 people who were addicted to cannabis treated with gabapentin showed a significant reduction in cannabis use and cannabis withdrawal compared to placebo. Moreover, 70 men addicted to cannabis were randomized and those, who used FAAH inhibitors reported fewer cannabis withdrawal symptoms, less cannabis use and lower THC urine levels than placebo users. Conclusions: Gabapentin has been proven to show a reduction in CUD. The use of CBD, FAAH inhibitors and psychotherapy MET/CBT/CM also appear to be effective. In addition, the use of the principles of People-First Language, avoiding slang and idioms, using medical and curing vocabulary, respects the addicted person, and also positively influences the chances of abstinence.